It is no surprise that many inhibitors of the PI3K-AKT-mTOR signaling pathway have been developed and have demonstrated efficacy in inhibiting CRC proliferation in preclinical studies [63, 76–78]. Here, AKT1 is linked to colorectal carcinoma.